Downregulation of microRNA-431 by human interferon-βinhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6

International Journal of Oncology

Volumn 44, Issue 5, 2014, Pages 1685-1690

  Tanaka, Takeshi ^a   Arai, Makoto ^b   Jiang, Xia ^b   Sugaya, Shigeru ^a   Kanda, Tatsuo ^b   Fujii, Katsunori ^c   Kita, Kazuko ^a   Sugita, Katsuo ^c   Imazeki, Fumio ^b   Miyashita, Toshiyuki ^d   Kaneda, Atsushi ^a   Yokosuka, Osamu ^b  

^a Departments of Molecular Oncology   (Japan)

^b Gastroenterology   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Cancer therapy; Cell viability; Human IFN ; JAK STAT signaling pathway; MicroRNA

Indexed keywords

JANUS KINASE 1; MICRORNA; MICRORNA 431; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RECOMBINANT BETA INTERFERON; STAT1 PROTEIN; STAT2 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 6; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; INTERFERON-BETA; MICRORNAS; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

EID: 84899120946     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2317     Document Type: Article

References (40)

1. Du T and Zamore PD: MicroPrimer: the biogenesis and function of microRNA. Development 132: 4645-4652, 2005. (Pubitemid 41685275)
2. He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet 5: 522-531, 2004. (Pubitemid 38868508)
3. Ambros V: The functions of animal microRNAs. Nature 431: 350-355, 2004.
4. Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297, 2004.
5. Lawler S and Chiocca EA: Emerging functions of microRNAs in glioblastoma. J Neurooncol 92: 297-306, 2009.
6. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 2435: 834-838, 2005. (Pubitemid 40839735)
7. Pfeffer LM: Mechanisms of Interferon Action. CRC Press, Boca Raton, FL, 1987.
8. Saito R, Mizuno M, Hatano M, et al: Two different mechanisms of apoptosis resistance observed in interferon-β induced apoptosis of human glioma cells. J Neurooncol 67: 273-280, 2004. (Pubitemid 39137357)
9. Yoshino A, Katayama Y, Yokoyama T, et al: Therapeutic implication of interferon regulatory factor 1 (IRF-1) and IRF-2 in diffusely infiltrating astrocytomas (DIA): response to IFN-β in glioblastoma cells and prognostic value for DIA. J Neurooncol 74: 249-260, 2005. (Pubitemid 41444490)
10. Petska S, Langer AJ, Zoon K, et al: Interferons and their action. Annu Rev Biochem 56: 727-777, 1987.
11. Taniguchi T and Takaoka A: The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14: 111-116, 2002. (Pubitemid 34085114)
12. Biron CA: Interferon alpha and beta as immune regulators - a new look. Immunity 14: 661-664, 2001.
13. Revel M and Chebath J: Interferon-activated genes. Trends Biochem Sci 11: 166-170, 1986. (Pubitemid 16115298)
14. Williams BR: Transcriptional regulation of interferon-stimulated genes. Eur J Biochem 200: 1-11, 1991.
15. Yoshida J, Kajita Y, Wakabayashi T, et al: Long-term follow-up results of 175 patients with malignant glioma: importance of radical tumor resection and post-operative adjuvant therapy with interferon, ACNU and radiation. Acta Neurochir 127: 55-59, 1994. (Pubitemid 24093475)
16. Tanaka T, Sugaya S, Kita K, et al: Inhibition of cell viability by human IFN-β is mediated by microRNA-431. Int J Oncol 40: 1470-1476, 2012.
17. Packer RJ and Vezina G: Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol 65: 1419-1424, 2008.
18. Ribi K, Relly C, landolt MA, et al: Outcome of medulloblastoma in children: long-term complications and quality of life. Neuropediatrics 36: 357-365, 2006.
19. Furnari FB, Fenton T, Bachoo RM, et al: Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 21: 2683-2710, 2007. (Pubitemid 350070717)
20. Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med 359: 492-507, 2008.
21. Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866, 2006. (Pubitemid 44629897)
22. Cho WC: OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6: 60, 2007.
23. Li KK, Pang JC, Ching AK, et al: miR-124 is frequently downregulated in medulloblastoma and is a negative regulator of SLC16A1. Hum Pathol 40: 1234-1243, 2009.
24. Silber J, Hashizume R, Felix T, et al: Expression of miR-124 inhibits growth of medulloblastoma cells. Neuro Oncol 15: 83-90, 2013.
25. Wu J, Qian J, Li C, et al: miR-129 regulates cell proliferation by downregulating Cdk6 expression. Cell Cycle 9: 1809-1818, 2010.
26. Wang XM, Zhang SF, Cheng ZQ, et al: MicroRNA383 regulates expression of PRDX3 in human medulloblastomas. Zhonghua Bing Li Xue Za Zhi 41: 547-552, 2012 (In Chinese).
27. Zhao WH, Wu SQ and Zhang YD: Downregulation of miR-124 promotes the growth and invasiveness of glioblastoma cells involving upregulation of PPP1R13L. Int J Mol Med 32: 101-107, 2013.
28. Lv Z and Yang L: miR-124 inhibits the growth of glioblastoma through the downregulation of SOS1. Mol Med Rep 8: 345-349, 2013.
29. Niu CS, Yang Y and Cheng CD: MiR-134 regulates the proliferation and invasion of glioblastoma cells by reducing Nanog expression. Int J Oncol 42: 1533-1540, 2013.
30. Bier A, Giladi N, Kronfeld N, et al: MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget 4: 665-676, 2013.
31. Chawla-Sarkar M, Leaman DW and Borden EC: Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 7: 1821-1831, 2001. (Pubitemid 32708654)
32. Chou YT, Lin HH, Lien YU, et al: EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 70: 8822-8831, 2010.
33. Guo C, Sah JF, Beard L, et al: The Non-coding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Gene Chromosomes Cancer 47: 939-946, 2008.
34. Kefas B, Godlewski J, Comeau L, et al: microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572, 2008.
35. Teramo A, Gattazzo C, Passeri F, et al: Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood 121: 3843-3854, S1, 2013.
36. Gao W, Xu J, Liu L, et al: A systematic-analysis of predicted miR-21 targets identifies a signature for lung cancer. Biomed Pharmacother 66: 21-28, 2012.
37. Kim MJ, Nam HJ, Kim HP, et al: OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett 335: 145-152, 2013.
38. Yamamoto K, Mizutani Y, Nakanishi H, et al: Significant antitumor activity of cationic multilamellar liposomes containing human interferon-β gene in combination with 5-fluorouracil against human renal cell carcinoma. Int J Oncol 33: 565-571, 2008.
39. Wakabayashi T, Hatano N, Kajita Y, et al: Initial and maintenance combination treatment with interferon-beta, MCNU (Ranimustine), and radiotherapy for patients with previously untreated malignant glioma. J Neurooncol 49: 57-62, 2000.
40. Motomura K, Natsume A, Kishida Y, et al: Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter. Cancer 117: 1721-1730, 2011.